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1. Introduction 
The dendritic cells (DCs) are the most powerful antigen-presenting cells (APC) specialized 
to induce and regulate immune responses (1,2). The clinical use as cellular adjuvants in 
vaccination strategies has been aided by the development of methodologies to generate 
large production of these cells in culture. DCs can be grown ex-vivo from blood monocytes 
(3,4,5) or enriched CD34+ progenitors (6,7), using combinations of several cytokines/growth 
factors. Since our laboratory in Oslo routinely uses enriched CD34+ stem cells as stem cell 
support following high dose radio- and chemotherapy, it was of interest to test if such cells 
also could be applied for vaccine purposes (8,9), with a long term strategy of combining the 
two forms of therapy.  
There are some publications indicating that CD34+ derived DC may work more efficiently 
as APC than those derived from monocytes (10), and recent data confirm that vaccine 
programs using CD34+ cell derived DCs lead to improved clinical results (11).  
However, most in vitro culture systems for production of DCs include serum (9,11,12).  
Since DCs are able to take up and process serum–derived antigens that are present in the cell 
cultures, such DC can when injected create unwanted reactions in the patients, in particular 
when fetal calf serum (FCS) is used. Thus, serum-free culturing condition is preferable, but in 
most previous culture experiments these conditions resulted in a lower yield of DCs (13,14).  
Recently we reported a protocol for producing DCs from monocytes by use of gas-
permeable Teflon bags and serum-free medium (15). We have used in the present study this 
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experience and have developed a similar serum-free culture system for CD34+ cell derived 
DC and investigated the optimal immunological properties of these cells.  
2. Materials and methods 
2.1. Growth factors, recombinant human cytokines and medium 
Flt-3 ligand (Flt-3L), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
interleukin-4 (IL-4), tumor necrosis factor-alpha (TNF-α) and stem cell factor (SCF) were 
purchased from CellGenix, Freiburg, Germany. Interferon-alpha (INF- α) was from Roche, 
Basel, Switzerland. Serum free medium CellGro/SCGM and CellGro/DC medium (CellGenix, 
Freiburg, Germany) were employed during the culture. To compare the serum free growth 
conditions with serum containing medium, CellGro/SCGM with 25% human albumin or 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FCS were used. 
Penicillin and Streptomycin was added to all mediums. 
 
Figure 1. CD34+ cells (three different samples) cultured in serum-free CellGro SCGM/DC medium with 
added cytokines (as shown in materials and methods). The graphs indicate the fold expansion over time 
2.2. CD34+ cell isolation  
Leukapheresis-harvested samples were obtained from cancer patients undergoing peripheral 
blood (PB) stem cell mobilization after informed consent, using a CS 3000 Fenwall Cell 
Separator (Baxter, Deerfield, IL, USA). The isolation of CD34+cells was carried out using an 
Isolex 300i magnetic cell selector (Nexell, Irvine, CA, version 2.5CE/2.5CE+) as described 
earlier (16). The CD34+ samples were frozen in liquid nitrogen using PBS with 10% DMSO 
and 40% human serum albumin. The purity and viability of thawed CD34+ cells used for 
DC production was >98% and >95% respectively.  
2.3. Generation of CD34+-derived DCs  
CD34+ cells were rapidly thawed in a 37ºC water bath and washed once with culture 
medium. Then cells (0.5-1x105/ml) were transferred into VueLifeTM FEP Teflon bags 
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(CellGenix, Freiburg, Germany) with serum containing DMEM/10% FCS medium, serum-
free CellGro/SCGM medium or CellGro/SCGM/25% human albumin respectively. The 
following cytokine cocktail was added: GM-CSF 1000u/ml, IL-4 500u/ml, TNF-α 50ng/ml, 
Flt-3L 150ng/ml and SCF 50ng/ml. The bags were cultured for 14 days at 37ºC/5% CO2. To 
keep a cell concentration of 105cells per ml through the entire culture period, re-feeding of 
the cells with culture medium employing equal concentration of cytokines was performed at 
weekly intervals. The serum-free medium cultures were from day 7, supplemented with 
CellGro DC medium instead of CellGro SCGM medium.  
 
Figure 2. Expansion fold on Day 14. Different initial concentrations of CD34+ cells incubated in 
different culture medium. Cell concentration 105/ml are expanded better than 104/ml especially in serum 
free medium 
2.4. Isolation of mRNA from cell line of human prostate cancer origin 
Prostate cancer cell line DU 145 obtained from American Type Culture Collection (ATCC), 
was cultured in RPMI 1640 supplemented with 10% FCS. The method employed for 
isolation of mRNA from the tumor cell line has been described earlier (15). Briefly, 5x107 
cells were washed with cold PBS and transferred to a 1.5 ml microtube. Five hundred 
microliter ice-cold 2% IGEPAL (polyoxyethylene 9 nonylphenyl ether) (Sigma-Aldrich) was 
added to lyse the cells. The supernatant containing the cytosol fraction was obtained after 
centrifugation (10000xG for 1 minute at 4°C) and transferred to a 1.5 ml tube placed on a 
cooling block (4°C). To the supernatant 80 µl 10% LiDS (Lithium Lauryl Sulfate) (Sigma-
Aldrich), 80 ul 5M LiCl (Lithium Chloride) (Sigma-Aldrich) and 0.5 ml Lysis & Binding 
Solution (Geno Vision) was added. Samples were frozen and stored at –80ºC until use. 
Isolation and purification of mRNA from the frozen or fresh samples were prepared in a 
GenoMTM-48 Robotic Workstation (Genovision AS, Oslo, Norway) following the procedure 
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as described by the manufacturer (GenoMTM-48, Automated mRNA Isolation Handbook, 
http:// www.qiagen.com /genovision/technical.htm). Denaturing agarose/formaldehyde gel 
electrophoresis was used to evaluate the quality of mRNA. The prepared mRNA was either 
used fresh or stored at -80°C until use.  
2.5. Transfection of tumor mRNA into immature DCs 
Teflon bags containing immature DCs (day14) were concentrated by centrifugation (600xG, 5 
min., 4°C), the supernatant was removed using a plasma extractor (FENWAL Laboratories, 
USA) and the cell pellet was transferred by a syringe to a 50 ml tube. After one additional 
wash by centrifugation, the DCs were resuspended in cold culture medium to give a final 
volume of 0.6-0.8 ml and placed in a 4°C cooling block until use. mRNA transfection was 
performed as described earlier (17) using a BTX ECM 830 square-wave electroporator 
(Genetronics Inc.,San Diego,CA). Electroporation settings were adjusted to single pulse, 500 
volt and 2 ms. The BTX-4mm electroporation cuvette (Genetronics Inc.) was washed twice 
with sterile DC culture medium. Then mRNA extracted from 5x107 cells (40 µl) was added to 
the prepared immature DCs and transferred to the electroporation cuvette . After 
eletroporation, DCs were transferred back into the tube and stored on the cooling block for 1 
min. before further incubation and maturation. All mock-mRNA transfected DCs used as 
control underwent electroporation following the same procedure as described above. The cell 
processing and electroporation procedure took place in a sterile laminar hood inside the GMP 
(good manufacturing practice) laboratory facility. In order to assess the transfection efficacy, 
immature DCs were also electroporated with enhanced green fluorescence protein (EGFP) 
mRNA as a reporter gene instead of mRNA from tumor. The experimental conditions used 
and the flow cytometry measurement has been described previously (17).   
2.6. Maturation of DCs in sterile VueLifeTM FEP Teflon bags  
The two cells, mRNA-transfected and mock-transfected DCs, were removed from the tube 
by a syringe and injected through a sterile sampling site coupler into VueLifeTM FEP Teflon 
bags. In order to mature the DCs, serum-free or serum-containing medium was 
supplemented with a mixture of the cytokines: 50 ng/ml TNF-α (CELLGenix, Freiburg) and 
1000u/ml INF-α (Sigma-Aldrich). The final cell concentration during the incubation at 37ºC 
with 5% CO2 for 72 hours was 5x105cells per ml.  
2.7. Cryopreservation of mature DCs  
The bag containing matured DC was centrifuged at 600xG for 10 minutes at room 
temperature. By the use of plasma extractor the supernatant was removed and the 
remaining DCs were transferred to a 50 ml tube. Following cell enumeration and sterility 
testing, cells were transferred into Nunc vials. The cryoprotectant solution was CellGro DC 
medium with 50% human albumin and 10% DMSO. The final cell concentration was 1x107 
cells/ml. Total volume in each Nunc vial was 500 μl. Freezing was performed in a control 
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rate freezer giving a rate of cooling of 1ºC/min to -40ºC with compensation for heat of fusion, 
then 1-2ºC/min to -90ºC. The prepared samples were thereafter transferred to liquid nitrogen 
and stored until use. The quality control of the frozen DCs consisted of sterility tests, 
phenotyping and viability testing by trypan blue staining before freezing and after thawing.  
2.8. Immunophenotyping of the cells 
Immature and mature DCs were phenotyped using the following panel of monoclonal 
antibodies: fluorescence isothiocyanate (FITC)- or phycoerythrin (PE)- conjugated anti-
human CD1a, CD14, CD40, CD33, CD34, HLA DR, CD80 (Becton Dickinson), and CD83, 
CD86 (Immunotech). Negative controls were isotype-matched irrelevant antibodies 
(Dakocytomation). Cells were analyzed by flow cytometry using a FACSsort (Becton 
Dickinson, San Jose, Ca, USA). 
2.9. Generation of T-cell responses in vitro by transfected DCs 
Autologous-T cells were stimulated four times with weekly intervals in vitro by transfected 
DCs as described before (15). Briefly, CD34- PBMC from the same patient were thawed and 
plated in 6-well plates to get rid of adherent cells. Non-adherent cells containing high 
numbers of T lymphocytes were collected and used as responder cells. Thawed mRNA-
transfected DCs used as stimulator cells were washed and irradiated with 3000 cGy. They 
were co-incubated in 24-well plates at a ratio 10:1 in serum-free CellGroDC-medium with 20 
ng/ml of IL-7 and 100 pg/ml of IL-12. After 7 days incubation at 37˚C in 5% CO2, 1 ml of the 
suspension from each well was replaced with 1 ml of fresh DC medium containing 20 ng/ml 
of IL-7. On day 12, 19 and 26 the responder cells were restimulated by new batches of 
thawed and irradiated transfected DCs as on day 0. On day 14, 21 and 28 the cell cultured 
were given 1 ml of DC medium containing 20 IU/ml of IL-2. Finally on day 33 the cells were 
harvested and tested using ELISPOT assay as described below.  
2.10. ELISPOT assay 
The conditions for the ELISPOT assay have been described previously (15). A 96 well plate 
(Millipore-MAIP N45) were coated with 75 μl antibodies against human IFN-γ (Mabtech 1-
D1K, 1 mg/ml diluted with PBS to a final concentration of 2 μg/ml) and incubated overnight at 
4˚C. The plate was left at room temperature (RT) for 1 hour and washed six times with PBS, 
200 μl/well. Then RPMI-1640 + 1% human albumin was added 100 μl/well and incubated for 1-
2 hours at 37˚C to block unspecific binding of the antibody. The responder cells and stimulator 
cells were transferred to the precoated wells in different cell concentrations. As control mock-
transfected DC, responder cells alone or medium alone was used. After incubation over night 
at 37˚C, the plates were washed six times with PBS/0.05% Tween. To each well 75 μl of a stock 
solution of 0.75 μg/ml Biotinylated antibody against human IFN- γ (Mabtech, 7-B6-1-biotin, 1 
mg/ml) was added and incubated for 2 hours at RT. Following six repeated washings the plate 
was incubated for one hour with 75μl per well of Streptavidin-ALP (Mabtech, 3310-8) from a 
stock solution (diluted 1:1000 in PBS+1%BSA). The plate was again washed 5 times with 
 Immunodeficiency 82 
PBS/0.05% Tween and one additional time with PBS alone. Then, after adding 75 µl of 
substrate BCIP/NBT (Sigma B911) to each well the plate was incubated for 4-5 minutes. When 
spots appeared, water was added to stop the reaction. The number of spots per well was 
counted under a stereomicroscope and the frequency of reactive T cells was calculated. 
3. Results 
3.1. Expansion of cells in serum-containing and serum-free medium 
CD34+ progenitors were cultured in Teflon bags using serum containing DMEM/10%FCS 
and serum-free CellGro SCGM/DC medium supplemented with cytokines as described 
above. Table 1 shows cell expansion and viability on day14. The total cell expansion is 
7.9±0.8 fold for CellGro/SCGM/DC medium and 8.3±0.6 fold for DMEM/FCS medium. Both 
conditions gave high cell viability, but when human albumin was added to the serum-free 
medium, lower cell expansion and viability was observed.  
CD34+ cells proliferate and differentiate very rapidly during the first week, while in the 
remaining culture period only a minor expansion took place. When different cell concentrations 
of CD34+ cells were seeded and cultured for 14 days, a cell concentration of 1x105 cells per ml 
kept through the culture period gave optimal growth conditions. Lower initial cell 
concentrations (1x104/ml) in the cultures gave no growth advantages (data not shown).  
3.2. Yield and phenotypes of immature and mature DCs 
Cultured cells lost their CD34 marker rapidly and no CD34 positive cells could be detected after 
7 days of culturing. At day 14, DC purity was 35.9 ± 7.7 % as assessed by expression of CD86 
and HLA DR antigens. Figure 2 (A and B) shows the phenotype of DCs in serum free medium 
on day 14 and 17. The CD86, CD83 and CD80 were up regulated greatly during maturation and 
the phenotypic profile obtained was comparable to DCs cultured in serum containing medium.  
Different transfection parameters with regard to voltages and time of exposure were tested 
and the most suitable protocol was found to be 500V at 2ms. By the use of these parameters a 
transfection efficacy of >95% could be achieved and the mean fluorescence levels using EGFP 
(Enhanced green fluorescent protein) were increased to about 100-fold above background 
(figure 3). The percentages of surviving DC following mRNA tranfection using propidium 
iodide staining were 76%. A similar survival was obtained in the mock-transfected DC.  
3.3. T-cell responses to thawed transfected DCs  
To assess the function of matured DCs we use transfected DCs to stimulate autologous T 
cells four times weekly. Thereafter the T cells were tested in the ELISPOT assay, which give 
information of both transfection efficacy, processing and antigen stimulation capacity of 
transfected DCs. As shown in figure 4, after four times stimulation by thawed transfected 
DCs in vitro, a significant and specific T-cell response to transfected DCs as compared to the 
control experiment employing mock-transfected DCs was achieved.  
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Figure 3. Immunophenotyping profile of: A) Immature DC; B) Mature DC generated from enriched 
monocytes. Overlay histograms show the expression of relevant antigens of immature (blue) and 
mature DC (green) versus isotype-matched control (red). The percentage of positive cells and mean 
fluorescence intensity value is shown too. 
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Figure 4. Transfection efficacy of mRNA demonstrated by utilized EGFP mRNA (lower part) compared 
to non-transfected DC (upper part). Left panels are density plots indicating large cell population gated. 
Middle panels are density plots showing the viability of cells (non-transfected and EGFP mRNA 
transfected by application of propidium iodide PI stating FL3). Right panels are histogram plots 
showing GFP signal in living cells. The green fluorescence intensity is increased about 100-fold in 
transfected cells than in non-transfected cells.  
4. Discussion 
In our hospital, enriched CD34+ stem cells are routinely being prepared and used as 
progenitor stem-cell support to patients receiving high dose therapy (16). In the cases that 
such patients also are candidates for DC-based vaccine treatment, spared frozen CD34+ cells 
would be available as a source for DC production thereby avoiding new expensive 
procedures for production of monocyte-derived DCs (18).  
The present study describes the establishment of a clinical ex- vivo culture system for 
expansion of mature DCs derived from CD34+ cells employing VueLifeTM FEP Teflon bags 
and serum free CellGro/SCGM/CellGro. Most methods applied for production of DC 
include FCS or pooled human serum. As a foreign protein, FCS is highly unwanted not only 
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because of the danger of disease transmission but also because immune responses against 
FCS might result in high background responses obscuring the specific T cell immunity. 
Other studies have indicated that human serum may inhibit DC differentiation and 
therefore seems not to be a good alternative to replace FCS (13). Serum free conditions have 
been tested previously (13,14). In these studies cell expansion and DC yield were very low 
though the phenotype of the DCs were considered not to be affected. In this study we have 
demonstrated that there is no difference between serum-free and serum-containing medium 
with regard to ex-vivo expansion of both the total number of cells and the estimated content 
of matured DCs in the cell products. The addition of serum albumin to our cultures did not 
result in any growth advantages. 
 
Figure 5. Autologous T cells stimulated with four times ex vivo irradiated transfected DC. ELISPOT 
assay indicates that stimulated T cells are able to recognize transfected DC specifically by use of mock-
transfected DC as conrol 
GM-CSF, TNF-α and IL-4 are cytokines that play an import role in DC differentiation (19,20) 
when serum-containing medium is being employed. However, our experiences and that of 
others indicate that this cytokine combination alone is not sufficient for ex vivo expansion of 
DCs from CD34+ cells. As described by others, ex-vivo culturing of CD34+ cells in the 
presence of SCF and Flt-3 (21) give an efficient expansion of total cell numbers without 
interfering with DC development. Since these early acting factors does not affect DC 
differentiation, but sustained the long-term expansion of CFU-DC, we chose to add them to 
our cultures. In contrast to monocyte- derived DCs, ex-vivo expansion of CD34 derived DCs 
usually occurred asynchronously over a 2 to 3 weeks period. Since INF-α can efficiently 
accelerate the course of maturation (22) we also included this cytokine in the cocktail the last 
3 days of culture. This resulted in an up regulation of the maturation antigens CD86, CD83 
and CD80.  
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The use of gas permeable bags for ex-vivo production has several advantages when 
compared to production in culture flasks. The bag system is closed and reduces the risk of 
contamination. DCs produced in Teflon bags do not attach to the surface and can easily be 
concentrated by centrifugation without any extra steps. It also facilitates large-scale 
production, which can be divided into aliquots containing cells with identical properties. 
We have shown that DCs can efficiently be produced in suspension using gas permeable 
Teflon bags. When CD34+ progenitors are cultured in flasks, usually the cell concentration is 
104/ml. In our system we have shown that optimal cell concentration is 105/ml, which give a 
10-fold reduction in the amount of medium and cytokines used. 
DCs have been loaded with several antigens, such as tumor lysate, peptides, proteins, DNA 
and mRNA. As a source of antigens, the major limitation of using lysate, proteins or peptides 
isolated from patients’ tumor cells is the amount of tumor tissue or the purity of the tumor 
specimens. The use of nucleic acids, either DNA or RNA, would overcome this practical 
limitation. As mRNA is a safer alternative due to its limited ability to cause permanent 
genetic alterations in the host, it appears to be more attractive to be used than DNA 
transfection (23). For this purpose, a vector-free transfection system based on square-wave 
electroporation to transfer mRNA into DCs has been developed (17). This method is currently 
successfully used in the clinic to produce mRNA-transfected monocyte-derived DCs (15). We 
here demonstrate that this method also resulted in efficient transfection of mRNA into 
immature CD34+ cell derived DCs without significantly affecting the survival of the cells.  
Generally the antigen-stimulating capacity of DCs has been evaluated employing allo-
reactive T cells or responses against recall antigens. We have used priming of autologous T 
cell against antigens encoded by a prostate tumor cell line in order to evaluate the immuno-
stimulatory role of the transfected DCs. The ELISPOT assay was used to detect and quantify 
of single T lymphocyte forming cytokine spots after antigen contact in vitro. The ELISPOT 
assay is a more stringent system for testing both the efficacy of transfection and the 
processing and antigen-stimulating capacity of transfected DCs. Our results show that 
CD34+ cells derived DCs, grown in serum free conditions in clinical scale productions 
reproducibly are capable of inducing a tumor specific immune response. These results are 
similar to what was seen in our previous study using monocyte-derived DCs 
The finding and results from the present study allows us to proceed with a clinical protocol for 
application of CD34+ derived DCs for cancer vaccine. Possible attractive candidates for such 
an approach are relapsed Hodgkin’s patients (16) and other patients that have previously been 
treated with auto transplantation and with spared frozen samples of CD34+ cells. 
 
Experiment Cell Gro/SCGM&25% HA DMEM / 10% FCS Cell Gro / SCGM / DC 
 fold / viability fold / viability fold / viability 
1 1.6 / 61% 9.0 / 97% 8.6 / 94% 
2 1.2 / 67% 7.8 / 98% 7.1 / 93% 
3 1.8 / 73% 8.8 / 97% 7.1 / 84% 
Table 1. Expansion fold and viability on Day 14 
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